Complementary and Alternative Therapies for the Management of Menopause-Related Symptoms

Nedrow, Anne; Miller, J. Mitchell; Walker, Miranda; Nygren, Peggy; Huffman, Laurie Hoyt; Nelson, Heidi D

doi:10.1001/archinte.166.14.1453

Cited by 232 publications

(112 citation statements)

References 94 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…interval) 50th 75th 90th 95th size Total mineral density, or reduce cancer risk (Cornwell et al, 2004;Messina et al, 2006;NAMS, 2000;Nedrow et al, 2006;Sacks et al, 2006;Sirtori et al, 2005).…”

Section: Sample Yearsmentioning

confidence: 99%

Estimating perchlorate exposure from food and tap water based on US biomonitoring and occurrence data

Huber

Blount

Mage

et al. 2010

J Expo Sci Environ Epidemiol

View full text Add to dashboard Cite

Section: Sample Yearsmentioning

confidence: 99%

Estimating perchlorate exposure from food and tap water based on US biomonitoring and occurrence data

Huber

Blount

Mage

et al. 2010

J Expo Sci Environ Epidemiol

View full text Add to dashboard Cite

“…16 Similarly, many women have turned to complementary and alternative therapies for the management of menopause-related symptoms. 17 However, many complementary and alternative therapies used for menopause-related symptoms are of unproven or limited benefit 17,18 , suggesting that patients should at least be informed of potential side-effects such as GERD.…”

Section: Commentmentioning

confidence: 99%

Postmenopausal Hormone Use and Symptoms of Gastroesophageal Reflux

Jacobson

Moy

Colditz

et al. 2009

Obstetrical &Amp; Gynecological Survey

View full text Add to dashboard Cite

Context-Previous studies suggest that elevated levels of estrogen and progesterone, either through endogenous or exogenous sources, increase gastroesophageal reflux.Objective-To evaluate the relationship between symptoms of gastroesophageal reflux disease and postmenopausal hormone therapy, including the use of selective estrogen receptor modulators and over-the-counter hormone preparations.Design, setting, and participants-Prospective cohort study of 51,637 postmenopausal women enrolled in the Nurses' Health Study who provided data on the use of hormone therapy biennially since 1976, and information about symptoms of gastroesophageal reflux in 2002.Main outcome measure-Self-reported symptoms of heartburn or acid-regurgitation occurring at least once a week in the previous year (reflux symptoms).Results-Among eligible participants, 12,018 (23%) women reported reflux symptoms. Compared to women who never used postmenopausal hormones, the multivariate odds ratio (OR) for the risk of reflux symptoms was 1.46 (95% CI 1.36-1.56) for past hormone users, 1.66 (95% CI 1.54-1.79) for current users of estrogen only, and 1.41 (95% CI 1.29-1.54) for current users of combined estrogen and progesterone. The risk of reflux symptoms increased significantly with increasing estrogen dose (P < 0.001) and increasing duration of estrogen use (P < 0.001). Moreover, current selective estrogen receptor modulator users experienced an OR of 1.39 (95% CI 1.22-1.59) for reflux symptoms, and women currently using over-the-counter hormone preparations had an OR of 1.37 (95% CI 1.16-1.62). Conclusions-Postmenopausal use of estrogens, selective estrogen receptor modulators, or overthe-counter hormone preparations is associated with an increased risk of symptoms of gastroesophageal reflux. This suggests a hormonal component to the pathophysiology of gastroesophageal reflux in women.

show abstract

“…It appears to have poor efficacy for menopausal symptoms. [64] • Black cohosh has been shown to be hepatotoxic.…”

Section: Complementary and Alternative Medicines (Cams)mentioning

confidence: 99%

South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014

Guidozzi

Alperstein²,

Bagratee

et al. 2014

S Afr Med J

View full text Add to dashboard Cite

The South African Menopause Society (SAMS) consensus position statement on menopausal hormone therapy (HT) 2014 is a revision of the SAMS Council consensus statement on menopausal HT published in the SAMJ in May 2007. Information presented in the previous statement has been re-evaluated and new evidence has been incorporated. While the recommendations pertaining to HT remain similar to those in the previous statement, the 2014 revision includes a wider range of clinical benefits for HT, the inclusion of non-hormonal alternatives such as selective serotonin reuptake inhibitors and serotonin noradrenaline reuptake inhibitors for the management of vasomotor symptoms, and an appraisal of bioidentical hormones and complementary medicines used for treatment of menopausal symptoms. New preparations that are likely to be more commonly used in the future are also mentioned. The revised statement emphasises that commencing HT during the 'therapeutic window of opportunity' maximises the benefit-to-risk profile of therapy in symptomatic menopausal women.

show abstract

Complementary and Alternative Therapies for the Management of Menopause-Related Symptoms

Cited by 232 publications

References 94 publications

Estimating perchlorate exposure from food and tap water based on US biomonitoring and occurrence data

Estimating perchlorate exposure from food and tap water based on US biomonitoring and occurrence data

Postmenopausal Hormone Use and Symptoms of Gastroesophageal Reflux

South African Menopause Society revised consensus position statement on menopausal hormone therapy, 2014

Contact Info

Product

Resources

About